FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $54,971 | -45.4% | 9,644 | -3.3% | 0.00% | -50.0% |
| Q4 2022 | $100,597 | -86.3% | 9,970 | -69.6% | 0.00% | -86.7% |
| Q3 2022 | $735,000 | -11.7% | 32,813 | -2.2% | 0.02% | -6.2% |
| Q2 2022 | $832,000 | -46.0% | 33,559 | -15.6% | 0.02% | -33.3% |
| Q1 2022 | $1,541,000 | -38.8% | 39,742 | -7.7% | 0.02% | -33.3% |
| Q4 2021 | $2,519,000 | +2.7% | 43,046 | +4.1% | 0.04% | -2.7% |
| Q3 2021 | $2,452,000 | -20.3% | 41,368 | +16.6% | 0.04% | -17.8% |
| Q2 2021 | $3,078,000 | +25.8% | 35,466 | +19.5% | 0.04% | +18.4% |
| Q1 2021 | $2,446,000 | +53.4% | 29,670 | +69.1% | 0.04% | +46.2% |
| Q4 2020 | $1,595,000 | +520.6% | 17,542 | +172.7% | 0.03% | +420.0% |
| Q3 2020 | $257,000 | +117.8% | 6,433 | +86.3% | 0.01% | +150.0% |
| Q2 2020 | $118,000 | – | 3,453 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |